<DOC>
	<DOCNO>NCT01085266</DOCNO>
	<brief_summary>An open-label extension study HORIZON protocol evaluate safety dimebon ( latrepirdine ) subject Huntington disease .</brief_summary>
	<brief_title>An Extension HORIZON Protocol Evaluating Safety Dimebon ( Latrepirdine ) Subjects With Huntington Disease</brief_title>
	<detailed_description />
	<mesh_term>Huntington Disease</mesh_term>
	<criteria>Successful completion 26 week blind treatment HORIZON study Any medical illness unstable medical condition may interfere ability comply study procedure abide study restriction , may interfere ability interpret safety information .</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>